Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2024, were $14.4 million, compared to $14.2 million for the same period in 2023. The increase was due ...

An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...

SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel ...

Iovance Biotherapeutics, Inc. is a commercial biotechnology company specializing in the development and delivery of tumor-infiltrating lymphocyte (TIL) therapies for cancer patients, with a focus on ...

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...

Researchers found that tumor-infiltrating lymphocyte (TIL) density may play an important role in predicting the response to combining immunotherapy with chemotherapy. According to study findings ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

XML Financial LLC increased its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 7.4% during ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $12.28, but opened at $10.67. Iovance Biotherapeutics ...

These cells are also called tumor-infiltrating lymphocytes (TIL). T cells are integral in the immune system but can become ...